MBLX Metabolix Inc

Yield10 Bioscience Announces Participation at The H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020 (Virtual Conference)

Yield10 Bioscience Announces Participation at The H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020 (Virtual Conference)

WOBURN, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced it will be featured as a presenting company at the H.C. Wainwright 22nd Annual Global Investment Conference. The conference is being held on September 14-16, 2020 virtually.

Oliver Peoples, Ph.D., President and Chief Executive Officer of Yield10, will provide an overview of the Company's business during the live presentation on Monday, September 14, 2020 at 11:00 am Eastern Time and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. 

If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link: to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

Event: H.C. Wainwright 22nd Annual Global Investment Conference (Virtual Conference)

Date: September 14, 2020

Time: 11:00 am Eastern Time

Location: Virtual Conference

Webcast URL:

About Yield10 Bioscience

Yield10 Bioscience, Inc. is an agricultural bioscience company developing crop innovations for sustainable global food security. The Company uses its “Trait Factory” including the “GRAIN” big data mining trait gene discovery tool as well as the Camelina oilseed “Fast Field Testing” system to develop high value seed traits for the agriculture and food industries. As a path toward commercialization of novel traits, Yield10 is pursuing a partnering approach with major agricultural companies to drive new traits into development for canola, soybean, corn, and other commercial crops. The Company is also developing improved Camelina varieties as a platform crop for the production and commercialization of nutritional oils, proteins, and PHA biomaterials. The Company’s expertise in oilseed crops extends into canola, where it is currently field testing novel yield traits to generate trait performance data to drive additional licensing opportunities. Yield10 is headquartered in Woburn, MA and has an Oilseeds Center of Excellence in Saskatoon, Canada.

For more information about the Company, and follow the Company on and  (YTEN-G)

Contacts: 

Yield10 Bioscience:

Lynne H. Brum, (617) 682-4693,

Investor Relations: 

Bret Shapiro, (561) 479-8566,

Managing Director, CORE IR

Media Inquiries:

Eric Fischgrund,

EN
09/09/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Metabolix Inc

 PRESS RELEASE

Yield10 Bioscience Announces Second Quarter 2024 Financial Results

Yield10 Bioscience Announces Second Quarter 2024 Financial Results WOBURN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the second quarter ended June 30, 2024. "We continue to work closely with the Nufarm team to finalize the asset purchase agreement announced in July,” said Oliver Peoples, Ph.D., President and Chief Executive Officer of Yield10. “We believe that the transition of our Omega-3 Camelina program to Nufarm is in the best interest of our sh...

 PRESS RELEASE

Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Asset...

Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets - Nufarm to pay up to USD $5 million in consideration for the license-The parties will negotiate the sale of essentially all of Yield10’s assets to Nufarm WOBURN, Mass. and WEST SACRAMENTO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (OTC:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company has signed a Memorandum of Understanding (“MOU”...

 PRESS RELEASE

Rothamsted Research Grants Yield10 Bioscience an Exclusive, Global Com...

Rothamsted Research Grants Yield10 Bioscience an Exclusive, Global Commercial License to Advanced Technology for Producing Omega-3 Products in Camelina Engineered Camelina is intended to enable the land-based production of omega-3 oils used in aquafeed, petfood and human nutrition WOBURN, Mass. and HARPENDEN, United Kingdom, June 17, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (OTC:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that U.K.-based Rothamsted Research Limited (“Rothamsted”) has granted to the Company an exclusive global, commerc...

 PRESS RELEASE

Yield10 Bioscience Announces Addition of Camelina to INTERLINE® Herbic...

Yield10 Bioscience Announces Addition of Camelina to INTERLINE® Herbicide Label - EPA approved an amendment to the label of INTERLINE herbicideto include Camelina -The supplemental label now allows application of INTERLINE for over-the-top weed control in Camelina WOBURN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (OTC:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that UPL Ltd. (“UPL”) has received U.S. Environmental Protection Agency (“EPA”) approval to of INTERLINE® Herbicide to include the oilseed Camelina sativa (“Came...

 PRESS RELEASE

Yield10 Bioscience Announces First Quarter 2024 Financial Results

Yield10 Bioscience Announces First Quarter 2024 Financial Results -Earns $1 million in milestone payments from Vision Bioenergy Oilseeds WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the first quarter ended March 31, 2024. "In the first quarter of 2024, we made the strategic decision to focus our resources on the commercialization of Camelina products targeting the aquafeed and nutritional markets for omega-3 fatty acids," said Oliver Peoples, ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch